Cargando…

Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study

BACKGROUND: Many men with elevated prostate-specific antigen (PSA) levels in serum do not have aggressive prostate cancer and undergo unnecessary biopsy. Retrospective studies using cryopreserved serum suggest that four kallikrein markers can predict biopsy outcome. METHODS: Free, intact and total P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bryant, Richard J., Sjoberg, Daniel D., Vickers, Andrew J., Robinson, Mary C., Kumar, Rajeev, Marsden, Luke, Davis, Michael, Scardino, Peter T., Donovan, Jenny, Neal, David E., Lilja, Hans, Hamdy, Freddie C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554254/ https://www.ncbi.nlm.nih.gov/pubmed/25863334 http://dx.doi.org/10.1093/jnci/djv095

Ejemplares similares

Alcohol consumption and PSA-detected prostate cancer risk—A case-control nested in the ProtecT study
por: Zuccolo, Luisa, et al.
Publicado: (2013)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study
por: Rosario, Derek J, et al.
Publicado: (2012)

Role of information in preparing men for transrectal ultrasound guided prostate biopsy: a qualitative study embedded in the ProtecT trial
por: Wade, Julia, et al.
Publicado: (2015)

The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression
por: Bryant, Richard J., et al.
Publicado: (2020)

Physical activity, alcohol consumption, BMI and smoking status before and after prostate cancer diagnosis in the ProtecT trial: Opportunities for lifestyle modification
por: Hackshaw-McGeagh, Lucy E, et al.
Publicado: (2015)

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands
por: Gupta, A, et al.
Publicado: (2010)

Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial
por: Wade, Julia, et al.
Publicado: (2015)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
por: Vickers, Andrew J, et al.
Publicado: (2008)

Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial
por: Johnston, Thomas J., et al.
Publicado: (2017)

Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial
por: Er, Vanessa, et al.
Publicado: (2017)

A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial
por: Donovan, Jenny L., et al.
Publicado: (2018)

The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer
por: Noble, Sian M., et al.
Publicado: (2020)

A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy
por: Haese, Alexander, et al.
Publicado: (2020)

Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study
por: Dimitropoulou, P, et al.
Publicado: (2011)

Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)
por: Lane, Janet Athene, et al.
Publicado: (2022)

Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study
por: Catto, J W F, et al.
Publicado: (2011)

Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial
por: Sanghera, S., et al.
Publicado: (2020)

Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial
por: Wade, Julia, et al.
Publicado: (2020)

A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France
por: Benchikh, Amine, et al.
Publicado: (2010)

He protec but he also attac – Inflammasomes swinging the sword()
por: Kattner, Aila Akosua
Publicado: (2023)

Copy Number Variants in the Kallikrein Gene Cluster
por: Lindahl, Pernilla, et al.
Publicado: (2013)

Evaluating best practice in informed consent discussions: a new method of evaluating information provision and patient understanding during trial recruitment consultations
por: Wade, Julia, et al.
Publicado: (2013)

Recruiters to randomised trials can be trained to facilitate recruitment and informed consent by exploring patients’ treatment preferences
por: Mills, Nicola, et al.
Publicado: (2013)

ProTec - A Normal-conducting Cyclinac for Proton Therapy Research and Radioisotope Production
por: Apsimon, Robert, et al.
Publicado: (2015)

Understanding factors influencing questionnaire response rates to maximise retention in a long term complex intervention trial
por: Lane, Athene J, et al.
Publicado: (2011)

Prostate cancer screening and management: Caution against over-interpreting the results of the latest study, ProtecT
por: Kim, Isaac Yi
Publicado: (2023)

Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy
por: Gilbert, Rebecca, et al.
Publicado: (2015)

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group
por: Roobol, Monique J., et al.
Publicado: (2011)

Exploring treatment preferences facilitated recruitment to randomized controlled trials
por: Mills, Nicola, et al.
Publicado: (2011)

Addressing patient treatment preferences at trial recruitment
por: Mills, Nicola, et al.
Publicado: (2011)

Prognostic significance of multiple kallikreins in high-grade astrocytoma
por: Drucker, Kristen L., et al.
Publicado: (2015)

Human kallikrein-2 gene and protein expression predicts prostate cancer at repeat biopsy
por: Satkunasivam, Raj, et al.
Publicado: (2014)

Vers une filtration aérienne active pour les patients contaminants : le dispositif AIR’Protec®
por: Viglino, Damien
Publicado: (2023)

Altered expression of epithelial-to-mesenchymal transition proteins in extraprostatic prostate cancer
por: Verrill, Clare, et al.
Publicado: (2015)

Kallikrein gene downregulation in breast cancer
por: Yousef, G M, et al.
Publicado: (2004)

Evaluation of source data verification in a multicentre cancer trial (PROTECT)
por: Lane, J Athene, et al.
Publicado: (2013)

Evolutionary History of Tissue Kallikreins
por: Pavlopoulou, Athanasia, et al.
Publicado: (2010)

Kallikreins as Biomarkers for Prostate Cancer
por: Hong, Sung Kyu
Publicado: (2014)

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study
por: Vickers, Andrew J, et al.
Publicado: (2013)

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
por: Vickers, Andrew J, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_gpp6g4vgrfd8kvu1m3evje56eb